Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers Use ‘Genomic Pathway’ to Predict Parkinson’s

15.06.2007
Findings detect 90-fold increased risk of developing disease; predict age of onset

A new Mayo Clinic study, published June 15 in PLoS Genetics, provides strong evidence that the joint effects of common DNA variations in several genes that encode proteins within a well-defined biological pathway largely explain why some persons get Parkinson’s disease while others don’t, and even predict with great accuracy at what age people might develop their first symptoms.

“This represents a major paradigm shift from single gene studies to genomic pathway studies of complex diseases,” says Demetrius Maraganore, M.D., the Mayo Clinic neurologist and Parkinson’s disease specialist who led the study.

The authors say traditional genetic studies have either discovered rare single gene mutations that cause Parkinson’s disease only in isolated families, or have identified common single gene variants that are only weakly associated with the disease and inconsistently across populations.

“By examining a large cluster of related genes, we found patterns that make people up to 90 times more likely to develop Parkinson’s than the average person,” says study co-author Timothy Lesnick, a Mayo Clinic biostatistician. “The size of the effects that we observed for genes within a pathway and the statistical significance of the predictive models were unprecedented.”

The models were highly effective in predicting age of onset of the disease: by age 60, 91 percent of patients in the highest-risk group already had Parkinson’s, while only 11 percent of patients in the lowest-risk group did. By age 70, every member of the highest-risk group had the disease, whereas two-thirds of patients in the lowest-risk group still were disease-free. Members of the highest-risk group typically developed Parkinson’s more than 20 years earlier than the lowest-risk group.

The researchers speculate that common genetic variations within the same biological pathway might also contribute to a person’s risk of developing other brain diseases; disorders, such as Alzheimer’s disease, Tourette’s syndrome, dyslexia, epilepsy and schizophrenia, need to be studied.

The study is significant because:

1)The genetic strategy was novel, investigating not just one, but many genes that were predicted to interact in a specific biologic pathway. This study provides a blueprint for the study of other complex diseases, which often have only modest associations with certain single genes. The summation of small effects from many genes in the same biologic pathway may be key to understanding many human diseases including Alzheimer’s, cardiovascular disease, diabetes, nicotine and alcohol dependence, and many cancers, in addition to Parkinson’s disease.

2)It provides intriguing new insights into the symptoms of Parkinson’s disease, and may lead to tests to identify persons at high risk, and to new treatments to prevent the disease or halt its progression.

3)These high-risk Parkinson’s disease genes were contained in the biologic pathway for the development of the human brain, as well as repair and remodeling of brain circuits (so-called axon guidance pathway). This raises speculation for another environmental influence that heretofore has been ignored: pre-birth events in the mother’s womb.

STUDY METHODS

The researchers studied the axon guidance pathway, which includes at least 128 genes that encode proteins that play a critical role in guiding the axons (or wiring) of the brain during fetal development. The same proteins also repair the wiring and determine the fate of damaged brain cells later in life.

The Mayo researchers analyzed a dataset that included information for hundreds of thousands of common DNA variants (single nucleotide polymorphisms or “SNPs”) in 443 Parkinson’s disease patients and in 443 control subjects; the controls were unaffected siblings. Researchers identified SNPs within axon guidance pathway genes and used statistical methods to identify combinations (“models”) of SNPs that were highly predictive of susceptibility to Parkinson’s disease, survival free of Parkinson’s disease, and age at onset of Parkinson’s disease. They then validated their findings using data from additional whole genome DNA and RNA variation datasets for Parkinson’s disease.

BACKGROUND THAT LED TO THE DISCOVERY

Dr. Maraganore and Mayo colleagues published the first whole-genome association study of Parkinson’s disease in 2005, studying hundreds of thousands of common DNA variants in the human genome, but as single and unrelated risk factors. They identified a dozen DNA variants that were weakly significant finding was for a DNA variant within the axon guidance pathway. This was the key clue in that first study, leading them to predict that this axon guidance pathway needed to be investigated. Thus, they focused on a few thousand variants within genes that encode that pathway, and analyzed their joint effects.

Dr. Maraganore compares the change in method to the difference between gazing at faint stars with a telescope versus looking at the Milky Way with the naked eye. “Instead of straining to observe the effects of single DNA variants scattered randomly across the universe of the human genome, we observed the effects of a constellation of variants within a well-defined genomic pathway,” he says. “When we looked at the axon guidance pathway in Parkinson’s disease in this way, it lit up.”

“ONE IN A TRILLION TRILLIONS”

“The effect of any single gene variant was small and of questionable significance, but the joint effects of multiple gene variants within the pathway were profound,” Lesnick explains. “Not only did we identify persons with as much as a 90 times greater risk for Parkinson’s disease, but we determined that the odds of our findings occurring by chance were less that one in a trillion trillions.” The findings were also validated in two independent datasets.

Still, the researchers caution that the predictive model findings need to be tested across global populations. They add that the axon guidance pathway should be studied in other diseases, and that other pathways should be studied in Parkinson’s disease, to add context to their findings. They also say mechanistic studies in experimental models will be required to understand precisely how variation in the axon guidance pathway leads to Parkinson’s disease.

BLUEPRINT FOR RESEARCH

The researchers say this is among the first times that information from a dataset of DNA variations across the whole genome has been employed to study the joint effects of a subset of DNA variations within a defined biological pathway (“genomic pathways” approach).

“This study serves as a blueprint for how we can study all complex disorders. By studying genomic pathways, we might be able to determine what causes people to be obese or to have hypertension, or to develop diabetes or heart disease,” Dr. Maraganore says.

IMPLICATIONS FOR PATIENTS

Parkinson’s disease is an aging-related disorder that affects nearly a million Americans. The cardinal signs include tremors, slowness of movements, and rigid body and limbs. The symptoms predominantly arise from progressive degeneration of brain cells that produce the chemical dopamine. “It is intriguing to consider that patients with Parkinson’s disease may be wired differently from birth,” adds co-author Eric Ahlskog, M.D., Ph.D., the head of Mayo Clinic’s Movement Disorders Section. “This might explain lifelong differences in personality, including avoidance of addictive substances and increased anxiety and depression. It might also explain asymmetries in the movement disorder that occurs in Parkinson’s disease; typically, one side of the body is affected predominantly.”

The findings could quickly lead to genetic tests to identify persons with a high probability of developing Parkinson’s disease during their lifetime. For example, a person with high predicted probability could have a risk of Parkinson’s disease that is 90 times greater than the average person; members of intermediate-risk groups would be four to 25 times more likely to develop Parkinson’s. The findings may also lead to development of new treatments that would promote the repair of damaged axons in the brain and spare nerve cells from early death, which could prevent or slow the progression of the disease.

MATERNAL HEALTH FACTORS

Researchers say that just as subtle genetic variations within the axon guidance pathway might alter brain wiring during fetal development and predispose to Parkinson’s disease decades later in life, subtle maternal health factors could also alter brain wiring and predispose to the disease.

The researchers say effects of maternal health on the risk of Parkinson’s disease should be explored in future studies. Until now, environmental studies of Parkinson’s disease have largely focused on adulthood exposures, such as to pesticides, smoking and coffee. These same exposures might contribute to the cause of Parkinson’s disease during gestation, they suggest.

The study was supported by grants from the National Institutes of Health, the Michael J. Fox Foundation, the National Parkinson Foundation Inc., and Gene Logic Inc.

Additional study co-authors include: Spiridon Papapetropoulos, M.D., Ph.D.; Deborah Mash, Ph.D.; and Lina Shehadeh, Ph.D., all of the University of Miami; Jarlath Ffrench-Mullen, Ph.D., of Gene Logic Inc.; Mariza de Andrade, Ph.D.; John Henley, Ph.D.; and Walter Rocca, M.D., all of Mayo Clinic.

Andrew Hyde | alfa
Further information:
http://www.plosgenetics.org

Further reports about: Axon DNA variants Maraganore Mayo Model Parkinson clinic common dataset disorder genetic variation guidance

More articles from Life Sciences:

nachricht A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht On the way to developing a new active ingredient against chronic infections
21.08.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

New bioimaging technique is fast and economical

21.08.2017 | Medical Engineering

Silk could improve sensitivity, flexibility of wearable body sensors

21.08.2017 | Materials Sciences

On the way to developing a new active ingredient against chronic infections

21.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>